

Adam S Garden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1401799/publications.pdf>

Version: 2024-02-01

373
papers

27,343
citations

5268

83
h-index

7745

150
g-index

381
all docs

381
docs citations

381
times ranked

17653
citing authors

#	ARTICLE	IF	CITATIONS
1	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 35-40.	1.7	3
2	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. <i>Acta Oncologica</i> , 2022, 61, 146-152.	1.8	1
3	Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors. <i>Head and Neck</i> , 2022, 44, 952-963.	2.0	2
4	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 426-436.	0.8	18
5	Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1132-1133.	1.6	0
6	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. <i>Scientific Reports</i> , 2022, 12, 6662.	3.3	2
7	Knowledge-based planning for the radiation therapy treatment plan quality assurance for patients with head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2022, 23, e13614.	1.9	11
8	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	6
9	Generating High-Quality Lymph Node Clinical Target Volumes for Head and Neck Cancer Radiation Therapy Using a Fully Automated Deep Learning-Based Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 801-812.	0.8	49
10	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. <i>British Journal of Cancer</i> , 2021, 124, 628-633.	6.4	17
11	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. <i>Radiotherapy and Oncology</i> , 2021, 157, 63-69.	0.6	4
12	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	4.1	2
13	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 98-103.	1.7	7
14	Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 37-44.	1.9	3
15	Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. <i>Laryngoscope</i> , 2021, 131, E1468-E1475.	2.0	18
16	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. <i>Oral Oncology</i> , 2021, 113, 105125.	1.5	12
17	Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. <i>Cancer</i> , 2021, 127, 1788-1795.	4.1	42
18	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. <i>Cancer</i> , 2021, 127, 2453-2464.	4.1	7

#	ARTICLE	IF	CITATIONS
19	The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. Journal of Geriatric Oncology, 2021, 12, 937-944.	1.0	5
20	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 469.	2.2	9
21	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. International Journal of Particle Therapy, 2021, 8, 261-272.	1.8	4
22	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. International Journal of Particle Therapy, 2021, 8, 234-247.	1.8	4
23	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. International Journal of Particle Therapy, 2021, 8, 213-222.	1.8	2
24	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Current Treatment Options in Oncology, 2021, 22, 54.	3.0	11
25	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. International Journal of Particle Therapy, 2021, 8, 108-118.	1.8	8
26	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiotherapy and Oncology, 2021, 159, 21-27.	0.6	12
27	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 374-382.	1.8	4
28	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 319-327.	1.8	11
29	18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2021, 29, 93-101.	1.7	6
30	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head and Neck, 2021, 43, 3331-3344.	2.0	15
31	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 615.	2.2	5
32	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiotherapy and Oncology, 2021, 160, 32-39.	0.6	18
33	Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. Cancer, 2021, 127, 4470-4480.	4.1	14
34	Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clinical and Translational Radiation Oncology, 2021, 30, 78-83.	1.7	1
35	Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention.. AMIA ... Annual Symposium proceedings, 2021, 2021, 979-988.	0.2	0
36	Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	2.0	25

#	ARTICLE	IF	CITATIONS
37	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	2.2	12
38	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 185-193.	0.8	12
39	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, 638-644.	0.8	7
40	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 133-139.	0.6	21
41	A prospective evaluation of health-related quality of life after skull base re-irradiation. <i>Head and Neck</i> , 2020, 42, 485-497.	2.0	3
42	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	4.1	8
43	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.6	24
44	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. <i>Advances in Radiation Oncology</i> , 2020, 5, 929-935.	1.2	8
45	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. <i>Radiotherapy and Oncology</i> , 2020, 151, 119-125.	0.6	10
46	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 71-78.	1.7	11
47	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 912.	2.6	31
48	Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. <i>Head and Neck</i> , 2020, 42, 3326-3335.	2.0	14
49	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. <i>Advances in Radiation Oncology</i> , 2020, 5, 1359-1363.	1.2	7
50	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 1-5.	2.9	9
51	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. <i>Radiotherapy and Oncology</i> , 2020, 148, 258-266.	0.6	21
52	Outcomes after radiation therapy for T2N0 stage II glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 2791-2800.	2.0	11
53	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. <i>Oral Oncology</i> , 2020, 106, 104665.	1.5	6
54	Regular Olâ€™™ Intensity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 615.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clinical and Translational Radiation Oncology, 2020, 22, 98-105.	1.7	5
56	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head and Neck, 2020, 42, 1939-1953.	2.0	29
57	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiotherapy and Oncology, 2020, 145, 95-100.	0.6	18
58	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiotherapy and Oncology, 2020, 148, 133-139.	0.6	11
59	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head and Neck, 2020, 42, 2137-2144.	2.0	3
60	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.8	156
61	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Practical Radiation Oncology, 2020, 10, 363-371.	2.1	3
62	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clinical Cancer Research, 2020, 26, 3211-3219.	7.0	64
63	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. Clinical and Translational Radiation Oncology, 2019, 18, 16-22.	1.7	24
64	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. Clinical and Translational Radiation Oncology, 2019, 18, 120-127.	1.7	24
65	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. Cancers of the Head & Neck, 2019, 4, 4.	6.2	8
66	Automatic detection of contouring errors using convolutional neural networks. Medical Physics, 2019, 46, 5086-5097.	3.0	72
67	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiation Oncology, 2019, 14, 148.	2.7	30
68	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 1053.	2.2	51
69	Not All 30-Gy Regimens Are Equal. Journal of Clinical Oncology, 2019, 37, 3558-3559.	1.6	3
70	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology, 2019, 3, 22.	5.4	31
71	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. Physics and Imaging in Radiation Oncology, 2019, 10, 29-34.	2.9	2
72	Development and validation of a 3D-printed bolus cap for total scalp irradiation. Journal of Applied Clinical Medical Physics, 2019, 20, 89-96.	1.9	29

#	ARTICLE	IF	CITATIONS
73	Postoperative Radiation Therapy for Metastatic Cervical Adenopathy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 144-149.	2.2	2
74	Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry. <i>Oral Oncology</i> , 2019, 91, 13-20.	1.5	25
75	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 724-733.	0.8	47
76	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	4.1	28
77	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. <i>Radiotherapy and Oncology</i> , 2019, 130, 46-55.	0.6	14
78	Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer. <i>Oral Oncology</i> , 2019, 88, 66-74.	1.5	103
79	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. <i>Radiotherapy and Oncology</i> , 2019, 133, 35-42.	0.6	16
80	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. <i>Cancer</i> , 2019, 125, 1536-1546.	4.1	19
81	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. <i>Journal of Neurosurgery</i> , 2019, 130, 812-821.	1.6	6
82	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. <i>Cancer</i> , 2018, 124, 1415-1427.	4.1	18
83	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. <i>Oral Oncology</i> , 2018, 79, 1-8.	1.5	6
84	In Regard to Routman et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1295-1296.	0.8	2
85	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.6	19
86	In Regard to Sher et al. <i>Practical Radiation Oncology</i> , 2018, 8, 66-67.	2.1	0
87	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	8
88	Auto-delineation of oropharyngeal clinical target volumes using 3D convolutional neural networks. <i>Physics in Medicine and Biology</i> , 2018, 63, 215026.	3.0	51
89	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching “liquid biopsy” and quantitative tumor modeling. <i>BMC Cancer</i> , 2018, 18, 903.	2.6	14
90	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.8	18

#	ARTICLE	IF	CITATIONS
91	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	1.7	41
92	Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head and Neck, 2018, 40, 2060-2069.	2.0	20
93	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid, 2018, 28, 945-951.	4.5	111
94	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clinical and Translational Radiation Oncology, 2018, 11, 11-18.	1.7	27
95	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	2.2	26
96	Decreased gastrostomy tube incidence and weight loss after transoral robotic surgery for low- to intermediate-risk oropharyngeal squamous cell carcinoma. Head and Neck, 2018, 40, 2507-2513.	2.0	15
97	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Scientific Data, 2018, 5, 180173.	5.3	51
98	Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 700-708.	0.8	46
99	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 532-540.	0.8	54
100	In Regard to Arthurs et al. International Journal of Radiation Oncology Biology Physics, 2017, 97, 440.	0.8	0
101	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	2.0	18
102	Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. Head and Neck, 2017, 39, 1516-1523.	2.0	32
103	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiotherapy and Oncology, 2017, 123, 401-405.	0.6	73
104	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope, 2017, 127, 842-848.	2.0	37
105	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer, 2017, 123, 1653-1661.	4.1	55
106	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head and Neck, 2017, 39, 633-638.	2.0	16
107	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiotherapy and Oncology, 2017, 124, 232-239.	0.6	69
108	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head and Neck, 2017, 39, 2079-2087.	2.0	15

#	ARTICLE	IF	CITATIONS
109	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiotherapy and Oncology, 2017, 124, 248-255.	0.6	32
110	Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. Practical Radiation Oncology, 2017, 7, e463-e470.	2.1	15
111	Transoral Robotic Surgery-Assisted Endoscopy. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1058.	2.2	0
112	Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head and Neck, 2017, 39, 2048-2056.	2.0	5
113	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clinical and Translational Radiation Oncology, 2017, 7, 28-35.	1.7	18
114	Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1002-1011.	0.8	86
115	Fabrication of an unconventional bolus-type stent for a combined intraoral/extraoral defect treated with proton radiation therapy. Journal of Prosthetic Dentistry, 2017, 117, 563-565.	2.8	7
116	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. International Journal of Radiation Oncology Biology Physics, 2017, 97, 687-699.	0.8	35
117	Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results Medicare Analysis. Cancer, 2017, 123, 283-293.	4.1	24
118	Surgical Treatment for T4 Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 96.	2.2	1
119	Atlas ranking and selection for automatic segmentation of the esophagus from CT scans. Physics in Medicine and Biology, 2017, 62, 9140-9158.	3.0	28
120	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. Radiation Oncology, 2017, 12, 150.	2.7	25
121	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. Radiation Oncology, 2017, 12, 129.	2.7	8
122	Design and fabrication of a 3D-printed oral stent for head and neck radiotherapy from routine diagnostic imaging. 3D Printing in Medicine, 2017, 3, 12.	3.1	31
123	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. Journal of Clinical Oncology, 2017, 35, 1969-1970.	1.6	3
124	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncology, 2017, 72, 90-97.	1.5	28
125	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. Radiation Oncology, 2016, 11, 95.	2.7	34
126	Depression and Oropharynx Cancer Outcome. Psychosomatic Medicine, 2016, 78, 38-48.	2.0	29

#	ARTICLE	IF	CITATIONS
127	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 1702-1707.	4.1	17
128	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. <i>Cancer</i> , 2016, 122, 534-545.	4.1	62
129	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. <i>Head and Neck</i> , 2016, 38, E452-8.	2.0	32
130	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. <i>Head and Neck</i> , 2016, 38, E925-33.	2.0	22
131	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	2.0	28
132	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1554-61.	2.0	11
133	Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. <i>Head and Neck</i> , 2016, 38, E2091-9.	2.0	14
134	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. <i>International Journal of Cancer</i> , 2016, 138, 1290-1297.	5.1	17
135	Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 180-189.	1.9	32
136	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. <i>Oral Oncology</i> , 2016, 63, 16-22.	1.5	7
137	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 344-352.	0.8	49
138	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. <i>Radiotherapy and Oncology</i> , 2016, 118, 315-322.	0.6	21
139	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. <i>Practical Radiation Oncology</i> , 2016, 6, 241-247.	2.1	41
140	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 304-314.	0.6	85
141	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 30-41.	0.8	123
142	Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. <i>Journal of Clinical Oncology</i> , 2016, 34, 2317-2318.	1.6	15
143	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. <i>Oral Oncology</i> , 2016, 61, 62-69.	1.5	29
144	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.6	177

#	ARTICLE	IF	CITATIONS
145	Larynx and Hypopharynx Cancer. , 2016, , 649-672.e4.		5
146	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. Radiotherapy and Oncology, 2016, 121, 381-386.	0.6	78
147	Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	2.0	33
148	In Regard to Kjems et al. International Journal of Radiation Oncology Biology Physics, 2016, 96, 240.	0.8	1
149	Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer, 2016, 122, 3411-3412.	4.1	1
150	Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head and Neck, 2016, 38, E1886-95.	2.0	102
151	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Medical Dosimetry, 2016, 41, 189-194.	0.9	62
152	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The ARTOG Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1346-1354.	0.8	28
153	Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. Head and Neck, 2016, 38, E580-7.	2.0	10
154	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head and Neck, 2016, 38, E1472-80.	2.0	36
155	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1117-1131.	0.8	100
156	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 782.	7.1	185
157	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.8	121
158	Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. Journal of Clinical Oncology, 2016, 34, 1848-1854.	1.6	64
159	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 360-367.	0.8	88
160	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncology, The, 2016, 17, 440-451.	10.7	607
161	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 523-531.	0.8	16
162	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. International Journal of Particle Therapy, 2016, 2, 533-543.	1.8	16

#	ARTICLE	IF	CITATIONS
163	Primary Mucosal Melanomas of the Head and Neck. , 2016, , 641-656.		0
164	A multimodality segmentation framework for automatic target delineation in head and neck radiotherapy. Medical Physics, 2015, 42, 5310-5320.	3.0	43
165	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organsâ€¢atâ€¢risk margination using daily CT onâ€¢rails imaging. Journal of Applied Clinical Medical Physics, 2015, 16, 159-169.	1.9	13
166	Radiationâ€¢associated malignancies of the ear canal and temporal bone. Laryngoscope, 2015, 125, 1198-1204.	2.0	12
167	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR in Biomedicine, 2015, 28, 1645-1654.	2.8	51
168	Reply to D. Adkins et al. Journal of Clinical Oncology, 2015, 33, 1224-1225.	1.6	0
169	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. Oral Oncology, 2015, 51, 195-201.	1.5	13
170	Quality Assurance Assessment of Diagnostic and Radiation Therapyâ€¢Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interestâ€¢based Comparison of Rigid and Deformable Algorithms. Radiology, 2015, 274, 752-763.	7.3	58
171	Reply to B. O'Sullivan et al. Journal of Clinical Oncology, 2015, 33, 1708-1709.	1.6	11
172	A multiâ€¢institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensityâ€¢modulated radiotherapy. Cancer, 2015, 121, 294-301.	4.1	109
173	A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Practical Radiation Oncology, 2015, 5, e169-e176.	2.1	40
174	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. International Journal of Radiation Oncology Biology Physics, 2015, 91, 721-729.	0.8	64
175	Longâ€¢term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3â€¢decade survey. Cancer, 2015, 121, 1608-1619.	4.1	100
176	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiotherapy and Oncology, 2015, 117, 132-138.	0.6	21
177	Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC).. Journal of Clinical Oncology, 2015, 33, 6001-6001.	1.6	4
178	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. International Journal of Particle Therapy, 2015, 2, 19-28.	1.8	76
179	Postoperative Intensity-Modulated Radiation Therapy for Head and Neck Cancers: A Case-Based Review. , 2015, , 193-213.		0
180	Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. Radiation Oncology, 2014, 9, 255.	2.7	39

#	ARTICLE	IF	CITATIONS
181	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 321-325.	0.6	96
182	The Never-Ending Story: Finding a Role for Neoadjuvant Chemotherapy in the Management of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2685-2686.	1.6	17
183	Forecasting longitudinal changes in oropharyngeal tumor morphology throughout the course of head and neck radiation therapy. <i>Medical Physics</i> , 2014, 41, 081708.	3.0	2
184	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventoryâ€Head and Neck Module. <i>Cancer</i> , 2014, 120, 1975-1984.	4.1	106
185	Longâ€term functional and survival outcomes after induction chemotherapy and riskâ€based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2014, 36, 474-480.	2.0	43
186	Letter to the Editor regarding transoral laser microsurgery followed by radiotherapy in advanced oropharyngeal cancer. <i>Head and Neck</i> , 2014, 36, 1674-1675.	2.0	0
187	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. <i>Head and Neck</i> , 2014, 36, 819-825.	2.0	5
188	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 619-626.	1.9	18
189	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 281-288.	0.6	54
190	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. <i>Practical Radiation Oncology</i> , 2014, 4, e31-e37.	2.1	28
191	Predicting oropharyngeal tumor volume throughout the course of radiation therapy from pretreatment computed tomography data using general linear models. <i>Medical Physics</i> , 2014, 41, 051705.	3.0	5
192	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3365-3373.	1.6	449
193	Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. <i>Journal of Clinical Oncology</i> , 2014, 32, 2940-2950.	1.6	697
194	Management of the lymph nodeâ€positive neck in the patient with human papillomavirusâ€associated oropharyngeal cancer. <i>Cancer</i> , 2014, 120, 3082-3088.	4.1	27
195	Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. <i>Practical Radiation Oncology</i> , 2014, 4, e189-e194.	2.1	22
196	Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 13-20.	0.8	198
197	Improved survival using intensityâ€modulated radiation therapy in head and neck cancers: A SEERâ€Medicare analysis. <i>Cancer</i> , 2014, 120, 702-710.	4.1	129
198	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 846-853.	0.8	128

#	ARTICLE	IF	CITATIONS
199	CT Findings in Temporal Bone Osteoradionecrosis. Journal of Computer Assisted Tomography, 2014, 38, 662-666.	0.9	13
200	An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center. Cancer, 2013, 119, 81-89.	4.1	145
201	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiation Oncology, 2013, 8, 21.	2.7	89
202	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 941-947.	0.8	99
203	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: A treatment planning comparison. Medical Dosimetry, 2013, 38, 390-394.	0.9	88
204	Osteoradionecrosis and Radiation Dose to the Mandible in Patients With Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 415-420.	0.8	209
205	Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. Head and Neck, 2013, 35, 1707-1712.	2.0	101
206	Adaptive radiotherapy for head and neck cancer—Dosimetric results from a prospective clinical trial. Radiotherapy and Oncology, 2013, 106, 80-84.	0.6	168
207	Anisotropic Margin Expansions in 6 Anatomic Directions for Oropharyngeal Image Guided Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 596-601.	0.8	11
208	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. Practical Radiation Oncology, 2013, 3, 186-193.	2.1	20
209	Identifying Early Dehydration Risk With Home-Based Sensors During Radiation Treatment: A Feasibility Study on Patients With Head and Neck Cancer. Journal of the National Cancer Institute Monographs, 2013, 2013, 162-168.	2.1	41
210	Prognostic Factors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 1195.	2.2	45
211	Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. Head and Neck, 2013, 35, 1599-1605.	2.0	52
212	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer, 2013, 119, 3162-3169.	4.1	49
213	Medical Physics, 2012, 39, 5136-5144.	3.0	20
214	Management of Radiation-Induced Severe Anophthalmic Socket Contracture in Patients With Uveal Melanoma. Ophthalmic Plastic and Reconstructive Surgery, 2012, 28, 208-212.	0.8	18
215	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncology, The, 2012, 13, 172-180.	10.7	291
216	Prediction of Neck Dissection Requirement After Definitive Radiotherapy for Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, e367-e374.	0.8	62

#	ARTICLE	IF	CITATIONS
217	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 204-209.	0.8	94
218	Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2012, 83, 986-993.	0.8	205
219	Hypopharyngeal Dose Is Associated With Severe Late Toxicity in Locally Advanced Head-and-Neck Cancer: An RTOG Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, 983-989.	0.8	61
220	Comparing surgery and radiation in the treatment of oropharyngeal cancer. Head and Neck, 2012, 34, 1198-1199.	2.0	0
221	Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. Cancer, 2012, 118, 2872-2878.	4.1	115
222	Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer, 2012, 118, 3928-3936.	4.1	165
223	Head and neck carcinoma in the United States. Cancer, 2012, 118, 5783-5792.	4.1	53
224	Radiation-associated head and neck sarcomas: Spectrum of imaging findings. Oral Oncology, 2012, 48, 155-161.	1.5	23
225	Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer. Radiation Oncology, 2012, 7, 19.	2.7	34
226	Larynx and Hypopharynx Cancer. , 2012, , 639-663.		2
227	Impact of Gender, Partner Status, and Race on Locoregional Failure and Overall Survival in Head and Neck Cancer Patients in Three Radiation Therapy Oncology Group Trials. International Journal of Radiation Oncology Biology Physics, 2011, 81, e101-e109.	0.8	29
228	Longitudinal oncology registry of head and neck carcinoma (LORHAN). Cancer, 2011, 117, 1679-1686.	4.1	41
229	Outcomes of malignant tumors of the lacrimal apparatus. Cancer, 2011, 117, 2801-2810.	4.1	62
230	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer Research, 2011, 17, 2035-2043.	7.0	81
231	SU-E-J-138: The Effect of Shoulder Variation on IMRT and SmartArc Plans for Head and Neck Cancer. Medical Physics, 2011, 38, 3474-3474.	3.0	0
232	Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head and Neck, 2010, 32, 473-480.	2.0	15
233	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head and Neck, 2010, 32, 829-836.	2.0	80
234	Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1333-1338.	0.8	336

#	ARTICLE	IF	CITATIONS
235	Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1â€“2 Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 455-461.	0.8	89
236	Prospective Imaging Assessment of Mortality Risk After Head-and-Neck Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 667-674.	0.8	21
237	Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases From Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1005-1010.	0.8	75
238	Response to Letter by Dr. Ibott et al.. International Journal of Radiation Oncology Biology Physics, 2010, 76, 639.	0.8	0
239	Candidate Dosimetric Predictors of Long-Term Swallowing Dysfunction After Oropharyngeal Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1356-1365.	0.8	156
240	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. Journal of Clinical Oncology, 2010, 28, 8-14.	1.6	234
241	To TORS or Not to TORS: But Is That the Question?. JAMA Otolaryngology, 2010, 136, 1085.	1.2	11
242	Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. Journal of Clinical Oncology, 2009, 27, 4727-4732.	1.6	40
243	Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer. Journal of Clinical Oncology, 2009, 27, 1976-1982.	1.6	47
244	Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving Radiation Therapy With or Without Chemotherapy. Journal of Pain and Symptom Management, 2009, 38, 522-532.	1.2	112
245	Controversies in Surgical Management of the Node-Positive Neck After Chemoradiation. Seminars in Radiation Oncology, 2009, 19, 24-28.	2.2	41
246	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A populationâ€“based study. Head and Neck, 2009, 31, 1031-1038.	2.0	30
247	Complications of radiotherapy in laryngopharyngeal cancer. Cancer, 2009, 115, 4636-4644.	4.1	78
248	Longitudinal oncology registry of head and neck carcinoma (LORHANÂ®): initial supportive care findings. Supportive Care in Cancer, 2009, 17, 1393-401.	2.2	17
249	IMRT Reirradiation of Head and Neck Cancerâ€”Disease Control and Morbidity Outcomes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 399-409.	0.8	218
250	Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1083-1091.	0.8	143
251	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 725-733.	0.8	80
252	Prospective Risk-Adjusted [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 2509-2515.	1.6	156

#	ARTICLE	IF	CITATIONS
253	Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. <i>Journal of Clinical Oncology</i> , 2009, 27, 3684-3690.	1.6	607
254	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. <i>Cancer</i> , 2008, 112, 111-118.	4.1	56
255	Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2008, 112, 2698-2709.	4.1	43
256	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. <i>Cancer</i> , 2008, 113, 2704-2713.	4.1	310
257	Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease. <i>Head and Neck</i> , 2008, 30, 675-679.	2.0	7
258	Postoperative radiotherapy for advanced medullary thyroid cancer—Local disease control in the modern era. <i>Head and Neck</i> , 2008, 30, 883-888.	2.0	78
259	Pretreatment Quality of Life Predicts for Locoregional Control in Head and Neck Cancer Patients: A Radiation Therapy Oncology Group Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 353-360.	0.8	61
260	Long-Term Radiotherapy Outcomes for Nasal Cavity and Septal Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 401-406.	0.8	55
261	Comparison of 2D Radiographic Images and 3D Cone Beam Computed Tomography for Positioning Head-and-Neck Radiotherapy Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 916-925.	0.8	112
262	Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 747-755.	0.8	168
263	The M. D. Anderson Symptom Inventory—Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1355-1361.	0.8	72
264	Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1351-1355.	0.8	101
265	Performance Evaluation of Automatic Anatomy Segmentation Algorithm on Repeat or Four-Dimensional Computed Tomography Images Using Deformable Image Registration Method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 210-219.	0.8	98
266	Salivary flow rates measured during radiation therapy in head and neck cancer patients: A pilot study assessing salivary sediment formation. <i>Journal of Prosthetic Dentistry</i> , 2008, 100, 142-146.	2.8	15
267	Psychosocial and Economic Impact of Cancer. <i>Dental Clinics of North America</i> , 2008, 52, 231-252.	1.8	8
268	Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5119-5125.	1.6	206
269	Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 3582-3589.	1.6	1,188
270	Postoperative Adjuvant External-Beam Radiation Therapy for Cancers of the Eyelid and Conjunctiva. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2008, 24, 444-449.	0.8	45

#	ARTICLE	IF	CITATIONS
271	Head and neck radiation and mucositis. Current Opinion in Supportive and Palliative Care, 2007, 1, 30-34.	1.3	10
272	The Effect of Dental Artifacts, Contrast Media, and Experience on Interobserver Contouring Variations in Head and Neck Anatomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 191-198.	1.3	33
273	TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncology, The, 2007, 8, 613-624.	10.7	191
274	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head and Neck, 2007, 29, 923-931.	2.0	227
275	Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer, 2007, 109, 1914-1922.	4.1	86
276	The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer, 2007, 109, 2052-2057.	4.1	49
277	Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 438-444.	0.8	130
278	Postoperative Radiotherapy for Maxillary Sinus Cancer: Long-Term Outcomes and Toxicities of Treatment. International Journal of Radiation Oncology Biology Physics, 2007, 68, 719-730.	0.8	86
279	Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck Malignancies. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1110-1120.	0.8	405
280	Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1369-1376.	0.8	44
281	Parotid Gland Dose in Intensity-Modulated Radiotherapy for Head and Neck Cancer: Is What You Plan What You Get?. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1290-1296.	0.8	130
282	Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study". Oral Oncology, 2007, 43, 98-105.	1.5	6
283	Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. International Journal of Clinical Oncology, 2007, 12, 99-110.	2.2	36
284	Xerostomia. , 2007, , 185-199.		1
285	Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. International Journal of Radiation Oncology Biology Physics, 2006, 64, 678-683.	0.8	83
286	Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1559-1569.	0.8	165
287	Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 469-476.	0.8	4
288	New thoughts on the pathobiology of regimen-related mucosal injury. Supportive Care in Cancer, 2006, 14, 516-518.	2.2	47

#	ARTICLE	IF	CITATIONS
289	How to reduce radiation-related toxicity in patients with cancer of the head and neck. Current Oncology Reports, 2006, 8, 140-145.	4.0	20
290	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 1: Fluorides. Oral Oncology, 2006, 42, 934-945.	1.5	13
291	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study. Oral Oncology, 2006, 42, 946-953.	1.5	17
292	Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. Cancer, 2006, 106, 1950-1957.	4.1	5
293	Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head and Neck, 2006, 28, 967-973.	2.0	70
294	Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck. Journal of Clinical Oncology, 2006, 24, 4163-4169.	1.6	59
295	Disadvantage of Men Living Alone Participating in Radiation Therapy Oncology Group Head and Neck Trials. Journal of Clinical Oncology, 2006, 24, 4177-4183.	1.6	59
296	Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13. Journal of Clinical Oncology, 2006, 24, 2092-2097.	1.6	97
297	Oral Complications of Cancer Therapy. , 2006, , 1349-1362.		0
298	Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. International Journal of Radiation Oncology Biology Physics, 2005, 62, 665-671.	0.8	43
299	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 717-724.	0.8	23
300	Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: Comparison of split-field and whole-field techniques. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1000-1005.	0.8	76
301	Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. Head and Neck, 2005, 27, 718-721.	2.0	42
302	Intensity-modulated radiotherapy: Is xerostomia still prevalent?. Current Oncology Reports, 2005, 7, 131-136.	4.0	33
303	Is There Still a Role for Induction Chemotherapy for Head and Neck Cancer?. Journal of Clinical Oncology, 2005, 23, 1059-1060.	1.6	10
304	Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14. Journal of Clinical Oncology, 2005, 23, 3008-3015.	1.6	151
305	Selective vs Modified Radical Neck Dissection and Postoperative Radiotherapy vs Observation in the Treatment of Squamous Cell Carcinoma of the Oral Tongue. JAMA Otolaryngology, 2005, 131, 874.	1.2	60
306	Validation of an accelerated "demonstrated" algorithm for deformable image registration in radiation therapy. Physics in Medicine and Biology, 2005, 50, 2887-2905.	3.0	537

#	ARTICLE	IF	CITATIONS
307	Carcinoma of the Paranasal Sinuses and Olfactory Neuroblastoma. , 2005, , 371-384.		1
308	Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck. Journal of Clinical Oncology, 2004, 22, 2856-2864.	1.6	177
309	A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 674-681.	0.8	119
310	Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. Journal of Oral and Maxillofacial Surgery, 2004, 62, 139-144.	1.2	56
311	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Seminars in Radiation Oncology, 2004, 14, 103-109.	2.2	62
312	Where are the at-risk cervical nodes?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1-2.	0.8	6
313	Radiation-induced Xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management. Head and Neck, 2004, 26, 796-807.	2.0	213
314	Parathyroid carcinoma: A 22-year experience. Head and Neck, 2004, 26, 716-726.	2.0	233
315	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer, 2004, 100, 383-389.	4.1	71
316	Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. Cancer, 2004, 100, 1171-1178.	4.1	87
317	A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer, 2004, 100, 991-998.	4.1	36
318	Sinonasal malignancies with neuroendocrine differentiation. Cancer, 2004, 101, 2567-2573.	4.1	187
319	Radiation therapy for early-stage carcinoma of the oropharynx. International Journal of Radiation Oncology Biology Physics, 2004, 59, 743-751.	0.8	62
320	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. International Journal of Radiation Oncology Biology Physics, 2004, 59, 960-970.	0.8	643
321	New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. Medical Dosimetry, 2004, 29, 86-91.	0.9	0
322	Mucositis: current management and investigations. Seminars in Radiation Oncology, 2003, 13, 267-273.	2.2	19
323	Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer, 2003, 97, 1789-1796.	4.1	110
324	Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer, 2003, 98, 2214-2223.	4.1	48

#	ARTICLE	IF	CITATIONS
325	Management of nonsinonasal neuroendocrine carcinomas of the head and neck. <i>Cancer</i> , 2003, 98, 2322-2328.	4.1	77
326	Results of radiotherapy for T2N0 glottic carcinoma: does the "stand for twice-daily treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 322-328.	0.8	130
327	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2002, 63, 187-193.	0.6	19
328	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2002, 95, 322-330.	4.1	54
329	Adult rhabdomyosarcoma. <i>Cancer</i> , 2002, 95, 377-388.	4.1	189
330	Electron conformal radiotherapy using bolus and intensity modulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 1023-1037.	0.8	56
331	ORGAN PRESERVATION FOR CARCINOMA OF THE LARYNX AND HYPOPHARYNX. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 243-260.	2.2	16
332	Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3010-3017.	1.6	115
333	Can positron emission tomography improve the quality of care for head-and-neck cancer patients?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 4-9.	0.8	61
334	Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 571-578.	0.8	566
335	Postoperative radiotherapy for malignant tumors of the submandibular gland. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 952-958.	0.8	68
336	A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 7-16.	0.8	1,222
337	Phase I/II Trial of Radiation With Chemotherapy "Boost" for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses. <i>Journal of Clinical Oncology</i> , 1999, 17, 2390-2390.	1.6	53
338	Radiation Therapy for Early Stage (T1-T2) Sarcomatoid Carcinoma of True Vocal Cords: Outcomes and Patterns of Failure. <i>Laryngoscope</i> , 1998, 108, 760-763.	2.0	53
339	Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: Outcomes and patterns of failure. , 1998, 20, 674-681.		122
340	Ethmoid sinus carcinomas: natural history and treatment results. <i>Radiotherapy and Oncology</i> , 1998, 49, 21-27.	0.6	65
341	Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. <i>Radiotherapy and Oncology</i> , 1997, 43, 53-61.	0.6	159
342	Radiation Therapy for Nonmelanoma Skin Carcinomas. <i>Clinics in Plastic Surgery</i> , 1997, 24, 719-729.	1.5	65

#	ARTICLE	IF	CITATIONS
343	Postoperative radiotherapy for malignant tumors of the parotid gland. International Journal of Radiation Oncology Biology Physics, 1997, 37, 79-85.	0.8	176
344	Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control. International Journal of Radiation Oncology Biology Physics, 1997, 37, 985-996.	0.8	265
345	Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. International Journal of Radiation Oncology Biology Physics, 1997, 39, 127-135.	0.8	47
346	Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma. , 1997, 79, 1279-1286.		56
347	Total Midface Reconstruction After Radical Tumor Resection. Annals of Plastic Surgery, 1996, 36, 551-557.	0.9	13
348	Phase II study of polymyxin B, tobramycin, and clotrimazole to prevent oral irradiation mucositis. Radiation Oncology Investigations, 1996, 4, 23-26.	0.9	0
349	Early squamous cell carcinoma of the hypopharynx: Outcomes of treatment with radiation alone to the primary disease. , 1996, 18, 317-322.		64
350	Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. Head and Neck, 1996, 18, 552-559.	2.0	134
351	Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1005-1012.	0.8	38
352	Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. International Journal of Radiation Oncology Biology Physics, 1996, 35, 455-462.	0.8	40
353	Olfactory Neuroblastoma and Neuroendocrine Carcinoma of the Anterior Skull Base: Treatment Results at the M.D. Anderson Cancer Center. Skull Base, 1996, 6, 1-8.	0.4	37
354	Minor salivary gland tumors of the palate: Clinical and pathologic correlates of outcome. Laryngoscope, 1995, 105, 1155-1160.	2.0	116
355	Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck. Cancer, 1995, 75, 2356-2360.	4.1	18
356	Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer, 1995, 76, 319-327.	4.1	185
357	Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1995, 31, 807-811.	0.8	17
358	Base-of-tongue carcinoma: Treatment results using concomitant boost radiotherapy. International Journal of Radiation Oncology Biology Physics, 1995, 33, 289-296.	0.8	69
359	The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. International Journal of Radiation Oncology Biology Physics, 1995, 32, 619-626.	0.8	401
360	Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: A comparison of two fractionation schedules. International Journal of Radiation Oncology Biology Physics, 1995, 31, 493-502.	0.8	51

#	ARTICLE	IF	CITATIONS
361	Water bolus for electron irradiation of the ear canal. International Journal of Radiation Oncology Biology Physics, 1995, 33, 479-483.	0.8	19
362	Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. International Journal of Radiation Oncology Biology Physics, 1995, 33, 179-182.	0.8	199
363	41 Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. International Journal of Radiation Oncology Biology Physics, 1995, 32, 161.	0.8	1
364	Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer, 1994, 73, 2563-2569.	4.1	172
365	Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M. D. Anderson cancer center experience. Head and Neck, 1994, 16, 39-44.	2.0	74
366	Postoperative radiotherapy for cutaneous melanoma of the head and neck region. International Journal of Radiation Oncology Biology Physics, 1994, 30, 795-798.	0.8	194
367	Primary carcinoma of the female urethra results of radiation therapy. Cancer, 1993, 71, 3102-3108.	4.1	64
368	Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial. International Journal of Radiation Oncology Biology Physics, 1993, 26, 3-11.	0.8	479
369	Carcinomas of the nasal cavity. Radiotherapy and Oncology, 1992, 24, 163-168.	0.6	39
370	Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiotherapy and Oncology, 1991, 20, 99-110.	0.6	128
371	Results of a changing treatment philosophy for children with stage I Hodgkin's disease: A 35-year experience. Medical and Pediatric Oncology, 1991, 19, 214-220.	1.0	10
372	Superior sulcus tumors: Treatment selection and results for 85 patients without metastasis (Mo) at presentation. International Journal of Radiation Oncology Biology Physics, 1990, 19, 31-36.	0.8	88
373	Association of hearing loss and tinnitus symptoms with <scp>healthâ€related</scp> quality of life among <scp>longâ€term</scp> oropharyngeal cancer survivors. Cancer Medicine, 0, , .	2.8	3